首页> 外文OA文献 >Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients

【2h】

Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients

机译：通过分阶段使用硼替佐米/沙利度胺/地塞米松治疗移植合格患者的骨髓瘤更新生存期和预后因素分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Chim Chor;
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients [J] . Chor S Chim Journal of Translational Medicine . 2010,第1期

机译：分阶段应用硼替佐米/沙利度胺/地塞米松治疗移植合格患者的骨髓瘤的更新生存率和预后因素分析
2. Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients [J] . Chor S Chim Journal of Translational Medicine . 2010,第1期

机译：分阶段应用硼替佐米/沙利度胺/地塞米松治疗移植合格患者的骨髓瘤的更新生存率和预后因素分析
3. Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: A meta-analysis [J] . LeibaM., KedmiM., DuekA., British Journal of Haematology . 2014,第5期

机译：硼替佐米-环磷酰胺-地塞米松（VCD）与以硼替佐米-沙利度胺-地塞米松（VTD）为基础的方案在新诊断为移植性多发性骨髓瘤患者中作为诱导疗法：荟萃分析
4. PROLONGED FOLLOW-UP STUDY OF AL PATIENTS INELIGIBLE FOR STEM CELL TRANSPLANTATION TREATED WITH ORAL MELPHALAN AND DEXAMETHASONE [C] . G Palladini, F Lavatelli, P Russo, International Symposium on Amyloidosis . 2008

机译：延长患者的延长后续研究，不符合口服梅酚和地塞米松治疗干细胞移植的患者
5. Plasma Cell Myeloma and Plasmacytoma-like Post-transplant Lymphoproliferative Disorders: A Survival Analysis in the Scientific Registry of Transplant Recipients. [D] . Rosenberg, Aaron. 2014

机译：浆细胞骨髓瘤和类浆细胞瘤样移植后淋巴组织增生性疾病：移植受体科学注册中的生存分析。
6. Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients [O] . Chor Sang Chim 2010

机译：分阶段使用硼替佐米/沙利度胺/地塞米松治疗移植合格患者的骨髓瘤的更新生存率和预后因素分析
7. Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients [O] . Chim Chor 2010

机译：分阶段使用硼替佐米/沙利度胺/地塞米松治疗移植合格患者的骨髓瘤的更新生存率和预后因素分析

Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients

著录项

相似文献

相关主题

期刊订阅